Anti-PD-1: Restoring T Cell Function in Cancer Immunotherapy by Assay Genie published on 2024-10-13T10:29:56Z https://www.assaygenie.com/anti-pd-1-restoring-t-cell-function-in-cancer-immunotherapy-b37783/ https://www.assaygenie.com/anti-mouse-pd-l1-b7-h1-10f-9g2-in-vivo-antibody-ultra-low-endotoxin/ Anti-PD-1 Therapy in Cancer Immunotherapy Source: "Anti-PD-1: Restoring T Cell Function in Cancer Immunotherapy" - Assay Genie Blog Post by Zainab Riaz, September 24, 2024 Main Themes: Anti-PD-1 therapy represents a revolutionary advance in cancer treatment. It enhances the immune system's ability to fight cancer by blocking the PD-1/PD-L1 interaction, which tumors exploit to evade immune surveillance. Understanding the PD-1/PD-L1 axis is crucial to understanding the mechanism of anti-PD-1 therapy. PD-1 on T cells, when engaged by PD-L1 expressed by tumor cells, leads to T cell suppression. Anti-PD-1 agents break this interaction, reactivating T cells. Anti-PD-1 therapy offers significant clinical benefits, but also carries the risk of immune-related adverse events (irAEs). Balancing efficacy with safety is a key consideration in treatment. Ongoing research focuses on optimizing anti-PD-1 therapy by improving patient selection, developing combination therapies, and overcoming resistance. Genre Science
